|
Hualan Biological Bacterin Inc. (301207.SZ) Évaluation DCF
CN | Healthcare | Biotechnology | SHZ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Hualan Biological Bacterin Inc. (301207.SZ) Bundle
Gardez un aperçu de votre analyse d'évaluation Hualan Biological Bacterin Inc. (301207SZ) en utilisant notre calculatrice sophistiquée DCF! Ce modèle Excel est préchargé avec des données réelles (301207SZ), vous permettant d'ajuster les prévisions et les hypothèses pour déterminer avec précision la valeur intrinsèque de Hualan Biological Bacterin Inc.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,049.0 | 2,426.3 | 1,829.8 | 1,825.6 | 2,410.4 | 3,056.5 | 3,875.8 | 4,914.7 | 6,232.1 | 7,902.6 |
| Revenue Growth, % | 0 | 131.3 | -24.59 | -0.22805 | 32.03 | 26.8 | 26.8 | 26.8 | 26.8 | 26.8 |
| EBITDA | 444.0 | 1,117.1 | 789.7 | 741.9 | 1,157.9 | 1,346.1 | 1,707.0 | 2,164.5 | 2,744.7 | 3,480.4 |
| EBITDA, % | 42.33 | 46.04 | 43.16 | 40.64 | 48.04 | 44.04 | 44.04 | 44.04 | 44.04 | 44.04 |
| Depreciation | 12.0 | 40.8 | 70.5 | 141.6 | 140.3 | 123.8 | 157.0 | 199.1 | 252.4 | 320.1 |
| Depreciation, % | 1.14 | 1.68 | 3.85 | 7.76 | 5.82 | 4.05 | 4.05 | 4.05 | 4.05 | 4.05 |
| EBIT | 432.1 | 1,076.3 | 719.3 | 600.3 | 1,017.6 | 1,222.3 | 1,550.0 | 1,965.4 | 2,492.3 | 3,160.3 |
| EBIT, % | 41.19 | 44.36 | 39.31 | 32.88 | 42.22 | 39.99 | 39.99 | 39.99 | 39.99 | 39.99 |
| Total Cash | 500.6 | 865.2 | 957.4 | 2,019.3 | 2,613.0 | 2,052.2 | 2,602.3 | 3,299.8 | 4,184.3 | 5,305.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 692.1 | 1,529.8 | 1,439.0 | 1,796.4 | 1,991.8 | 2,376.1 | 3,013.1 | 3,820.7 | 4,844.8 | 6,143.5 |
| Account Receivables, % | 65.97 | 63.05 | 78.64 | 98.4 | 82.63 | 77.74 | 77.74 | 77.74 | 77.74 | 77.74 |
| Inventories | 55.8 | 45.3 | 107.4 | 167.2 | 173.5 | 179.8 | 228.0 | 289.1 | 366.5 | 464.8 |
| Inventories, % | 5.32 | 1.87 | 5.87 | 9.16 | 7.2 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 |
| Accounts Payable | 15.3 | 105.5 | 185.5 | 125.7 | 116.8 | 169.2 | 214.5 | 272.0 | 344.9 | 437.4 |
| Accounts Payable, % | 1.46 | 4.35 | 10.14 | 6.88 | 4.84 | 5.53 | 5.53 | 5.53 | 5.53 | 5.53 |
| Capital Expenditure | -143.9 | -532.3 | -636.1 | -92.6 | -62.6 | -477.4 | -605.3 | -767.6 | -973.3 | -1,234.2 |
| Capital Expenditure, % | -13.72 | -21.94 | -34.76 | -5.07 | -2.6 | -15.62 | -15.62 | -15.62 | -15.62 | -15.62 |
| Tax Rate, % | 14.59 | 14.59 | 14.59 | 14.59 | 14.59 | 14.59 | 14.59 | 14.59 | 14.59 | 14.59 |
| EBITAT | 375.3 | 926.8 | 632.9 | 529.2 | 869.1 | 1,062.3 | 1,347.0 | 1,708.1 | 2,165.9 | 2,746.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -489.1 | -301.7 | 176.0 | 101.1 | 736.3 | 370.5 | 258.9 | 328.3 | 416.3 | 527.9 |
| WACC, % | 7.98 | 7.98 | 7.98 | 7.98 | 7.98 | 7.98 | 7.98 | 7.98 | 7.98 | 7.98 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,491.9 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 549 | |||||||||
| Terminal Value | 13,802 | |||||||||
| Present Terminal Value | 9,403 | |||||||||
| Enterprise Value | 10,895 | |||||||||
| Net Debt | -341 | |||||||||
| Equity Value | 11,236 | |||||||||
| Diluted Shares Outstanding, MM | 602 | |||||||||
| Equity Value Per Share | 18.65 |
What You Will Receive
- Genuine Hualan Biological Data: Pre-populated with Hualan's historical and forecasted figures for accurate analysis.
- Completely Customizable Template: Easily adjust essential inputs such as revenue growth, WACC, and EBITDA percentage.
- Instantaneous Calculations: Observe real-time updates to Hualan's intrinsic value based on your modifications.
- Expert Valuation Tool: Tailored for investors, analysts, and consultants aiming for precise DCF evaluations.
- User-Friendly Interface: Streamlined layout and clear guidance suitable for all levels of expertise.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Hualan Biological Bacterin Inc. (301207SZ).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs to fit your analysis.
- Customizable Forecast Assumptions: Easily adjust growth rates, capital expenditures, and discount rates to suit Hualan Biological Bacterin Inc. (301207SZ).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Hualan Biological Bacterin Inc. (301207SZ).
- Interactive Dashboard and Charts: Visual outputs that summarize essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review the pre-filled data for Hualan Biological Bacterin Inc. (301207SZ) including historical and projected figures.
- Step 3: Modify key assumptions (highlighted in yellow) based on your analysis.
- Step 4: Observe automatic recalculations of Hualan Biological Bacterin Inc.'s (301207SZ) intrinsic value.
- Step 5: Utilize the results for your investment decisions or reporting needs.
Why Choose Hualan Biological Bacterin Inc. (301207SZ) Calculator?
- Time-Efficient: Skip the hassle of building a DCF model from the ground up – it's fully prepared for your use.
- Enhanced Accuracy: Dependable financial data and formulas minimize valuation errors.
- Completely Customizable: Adjust the model to align with your specific assumptions and forecasts.
- User-Friendly: Intuitive charts and outputs simplify the analysis of results.
- Endorsed by Professionals: Crafted for experts who prioritize accuracy and functionality.
Who Can Benefit from Hualan Biological Bacterin Inc.?
- Investors: Assess Hualan Biological’s market valuation prior to making stock trades.
- CFOs and Financial Analysts: Optimize valuation workflows and evaluate financial forecasts.
- Startup Founders: Understand the valuation methodologies applied to established biotech firms like Hualan.
- Consultants: Provide clients with comprehensive valuation reports for informed decision-making.
- Students and Educators: Utilize up-to-date data for practical exercises and instruction in valuation practices.
Contents of the Template
- Pre-Filled Data: Contains Hualan Biological Bacterin Inc.'s historical financial information and projections.
- Discounted Cash Flow Model: An editable DCF valuation model with automatic calculations included.
- Weighted Average Cost of Capital (WACC): A separate sheet for WACC calculations based on user-defined inputs.
- Key Financial Ratios: Evaluate Hualan's profitability, operational efficiency, and capital structure.
- Customizable Inputs: Easily modify revenue growth rates, profit margins, and tax rates.
- Clear Dashboard: Visual representations such as charts and tables summarizing essential valuation metrics.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.